New Obesity Drug Targets Fat Storage Instead of Appetite in Early Trials
AT7687 blocks fat storage signals rather than suppressing hunger, showing early safety wins and metabolic benefits in first-in-human data.
Summary
A biotech company called Antag Therapeutics is developing a new obesity drug that works differently from popular GLP-1 treatments like Ozempic. Instead of reducing appetite, AT7687 blocks a receptor linked to how the body stores fat. In a first-in-human study presented at the American Diabetes Association's 2026 conference, the drug was well tolerated, caused no serious side effects, and showed minimal gastrointestinal issues — a common complaint with existing drugs. Early data also showed reductions in LDL cholesterol and resting heart rate. When combined with another weight-loss compound called cagrilintide in primate studies, the pairing produced double-digit weight loss, better insulin sensitivity, and preferential fat loss over muscle — without increasing appetite suppression. The results suggest a fundamentally different approach to obesity treatment.
Detailed Summary
Obesity treatment has long focused on eating less, but a new drug candidate is asking a different question: what if the body simply stores energy too efficiently? Antag Therapeutics presented early human trial data for AT7687 at the American Diabetes Association's 2026 Scientific Sessions, offering a glimpse at a mechanism that could complement or eventually rival GLP-1 drugs.
AT7687 is a first-in-class peptide that targets the GIP receptor, a pathway involved in fat storage and insulin regulation — not hunger signaling. In its first-in-human study involving healthy volunteers and people with obesity, the drug demonstrated a clean safety profile: no serious adverse events, no drug-related dropouts, and gastrointestinal side effects comparable to placebo. It also showed early signals of broader metabolic benefit, including reductions in LDL cholesterol and resting heart rate.
The more striking data came from preclinical combination studies. When AT7687 was paired with cagrilintide — a compound already known for weight reduction — obese, insulin-resistant primates achieved low double-digit percentage weight loss that did not plateau over time. Crucially, food intake was similar to animals receiving cagrilintide alone, meaning the extra weight loss came from how the body processed energy, not from eating less. The combination also favored fat loss over lean muscle mass and improved insulin sensitivity.
These findings matter because body composition and insulin sensitivity are stronger predictors of long-term health and longevity than weight alone. Preserving muscle while losing fat, and improving how cells respond to insulin, are outcomes that directly reduce risk of metabolic disease, cardiovascular events, and accelerated aging.
Caveats are significant: this is early-stage data, and human combination trials have not yet been reported. Preclinical primate results do not guarantee human outcomes. Investors and patients should watch for Phase 2 results before drawing firm conclusions about efficacy.
Key Findings
- AT7687 targets GIP receptor fat storage pathways, not appetite, offering a mechanistically distinct obesity treatment option.
- First-in-human trial showed no serious adverse events and GI side effects similar to placebo across all doses tested.
- Combined with cagrilintide in primates, AT7687 produced low double-digit weight loss without increasing appetite suppression.
- The drug combination preferentially reduced fat mass over lean muscle, a key marker for healthy aging and metabolic function.
- Early signals include reductions in LDL cholesterol and resting heart rate, suggesting broader cardiometabolic benefits.
Methodology
This is a news report summarizing early clinical and preclinical data presented at a major scientific conference, not a peer-reviewed publication. The source, Longevity.Technology, is a credible longevity-focused outlet, but the underlying data has not yet been published in a journal. Evidence basis is conference presentations and company-issued findings, which carry preliminary weight only.
Study Limitations
All combination efficacy data is preclinical and from primate models, which may not translate to humans. Human trials of AT7687 are at Phase 1 safety stage only, with no published efficacy data in people. Independent peer-reviewed publication of trial results has not yet occurred and should be verified before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.